Ongoing Clinical Trials for Ovarian Epithelial Cancer Stage IV
There are currently 2 ongoing clinical trials focused on Stage IV ovarian epithelial cancer. These trials are testing new treatment approaches including combination therapies with PARP inhibitors and angiogenesis inhibitors, as well as experimental medications targeting advanced and metastatic solid tumors.
Clinical trial locations
- Belgium
- France
- Italy
- Spain
Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors
This trial is testing a new medication called DS-3939a for patients with advanced cancers that have spread to other parts of the body. The medication is given directly into the bloodstream through an intravenous infusion.
Main inclusion criteria: To join this study, you must sign an informed consent form and have adequate organ function with a heart pumping efficiency of at least 50%. You need to have cancer that can be measured using standard imaging criteria and be able to carry out daily activities with minimal restrictions. For Part 1 of the study, patients with confirmed advanced cancer in the bladder, lung, breast, ovary, bile duct, or pancreas may participate. For Part 2, patients must have shown disease progression during or after their most recent treatment and be able to provide a tumor sample.
Main exclusion criteria: You cannot participate if you have certain types of metastatic or advanced solid tumors that don’t meet the study requirements, are outside the specified age range, belong to a vulnerable population such as pregnant women, or don’t meet the safety requirements for taking DS-3939a.
Focus and goal: The study has two parts. The first part focuses on understanding whether DS-3939a is safe and how well the body tolerates it. The second part continues to monitor safety while also measuring how effective the medication is at shrinking or controlling tumors. Throughout the trial, participants will have regular check-ups, laboratory tests, heart monitoring, and imaging studies to track their progress and watch for any side effects.
Investigational drug: DS-3939a is an experimental medication designed to target specific pathways that cancer cells use to grow and spread. It is being tested to see if it can safely and effectively treat advanced solid tumors.
Study on the Effectiveness of Olaparib and Bevacizumab for Maintenance Treatment in Patients with HRD-Positive Ovarian Cancer
This trial is studying the effectiveness of combining two medications, olaparib and bevacizumab, as maintenance therapy for patients with advanced, high-grade epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer. The study focuses on patients whose tumors have a specific genetic characteristic called homologous recombination deficiency (HRD).
Main inclusion criteria: You must be at least 18 years old with a new diagnosis of high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer at an advanced stage (FIGO stage III-IV). You need to provide tumor samples for testing and be suitable to receive platinum-taxane chemotherapy along with bevacizumab. You must have normal organ and bone marrow function, controlled blood pressure, and be able to perform light work or be fully active. A life expectancy of at least 16 weeks is also required.
Main exclusion criteria: You cannot participate if you don’t have a confirmed diagnosis of the specified cancers, are not eligible to start chemotherapy with bevacizumab, or if your tumor samples don’t test positive for HRD status. Patients who don’t achieve at least a partial response after initial platinum-based chemotherapy plus bevacizumab, or who don’t have a BRCA1-2 mutation, cannot join. You must also meet other specific eligibility criteria for starting treatment with olaparib.
Focus and goal: The study aims to confirm how well the combination of olaparib and bevacizumab works in preventing cancer from returning after initial treatment. Patients who respond well to their first round of chemotherapy with bevacizumab and have HRD-positive tumors will continue taking olaparib tablets along with bevacizumab as maintenance therapy. The trial will monitor how patients respond over time and gather information about the safety and effectiveness of this treatment approach.
Investigational drugs: Olaparib is a PARP inhibitor that blocks a protein cancer cells need to repair their DNA, which leads to the death of cancer cells. It is taken orally as tablets. Bevacizumab is a monoclonal antibody given through intravenous infusion that blocks the formation of new blood vessels that tumors need to grow, thereby cutting off their blood supply.
Summary
The two ongoing clinical trials for Stage IV ovarian epithelial cancer represent different treatment approaches. One trial is testing an experimental therapy (DS-3939a) for various advanced solid tumors including ovarian cancer, conducted across multiple European countries (Belgium, France, and Spain). The other trial, conducted in Italy, focuses specifically on maintenance treatment for HRD-positive ovarian cancer using an established combination of olaparib and bevacizumab.
The geographic distribution shows research activity spread across Southern and Western Europe. The trials differ in their approach: one explores a novel investigational drug while the other studies an established combination therapy to confirm its effectiveness in a specific patient population with genetic markers that may make them more responsive to treatment.
